STOCK TITAN

Ginkgo Bioworks Holdings Inc - DNA STOCK NEWS

Welcome to our dedicated news page for Ginkgo Bioworks Holdings (Ticker: DNA), a resource for investors and traders seeking the latest updates and insights on Ginkgo Bioworks Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ginkgo Bioworks Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ginkgo Bioworks Holdings's position in the market.

Rhea-AI Summary
Il Granaio delle Idee and Ginkgo Bioworks collaborate to enhance sourdough strains for bakery products using ALE technology. IGDI's Pater product aims to improve flavor, aroma, and shelf life of baked goods, with Ginkgo's support. The partnership seeks to innovate and optimize sourdough production for artisanal and industrial bakers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.84%
Tags
none
-
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) hosts its 5th annual Ferment conference, showcasing advancements in cell programming and biosecurity. CEO Jason Kelly highlights the value of Ginkgo's platform for customers across industries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
none
-
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) acquires AgBiome's platform assets, including over 115,000 fully sequenced strains and 500 million gene sequences, enhancing Ginkgo's ag biological discovery platform. AgBiome's validated product concepts offer a strong foundation for future developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) expands its strategic partnership with Novo Nordisk to enhance manufacturing of medicines for chronic diseases. The partnership aims to improve R&D, technology exploration, and scalable manufacturing solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
none
-
Rhea-AI Summary
Ginkgo Bioworks and Northeastern University researchers receive a grant from the Bill & Melinda Gates Foundation to develop an AI-enabled measles forecasting model to enhance public health measures. The model aims to assess outbreak risks and support timely interventions using traditional and non-traditional data sources, AI techniques, and open-access availability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.45%
Tags
AI
-
Rhea-AI Summary
IdeeLab Biotechnology partners with Ginkgo Bioworks to enhance biological solutions for agriculture. IdeeLab will provide local strain discovery and manufacturing capabilities to Ginkgo's customers, enabling the development of next-generation products in Brazil's biologicals market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) to host Ferment conference on April 11, 2024, bringing together stakeholders in synthetic biology. Livestream available for public access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.83%
Tags
conferences
-
Rhea-AI Summary
Prozomix and Ginkgo Bioworks announce a partnership to develop next-generation enzyme plates for API manufacturing. The collaboration aims to leverage Ginkgo's AI/ML models and Prozomix's enzyme libraries to create innovative biocatalysts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.81%
Tags
none
-
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) acquires Modulus Therapeutics' cell therapy platform assets, enhancing cell therapy capabilities. Modulus' CAR and switch receptor libraries improve control and performance of immune cell-based therapies, potentially increasing safety and efficacy. Ginkgo aims to support customers in developing T-cell and NK-cell based CAR therapies for various diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
Rhea-AI Summary
Ginkgo Bioworks (NYSE: DNA) secures a $6 million contract from DARPA for the ICE program to develop novel biologically-sourced materials for ice control in extreme cold weather environments, potentially impacting commercial markets like optics, aviation, automobiles, and outdoor products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.45%
Tags
none
Ginkgo Bioworks Holdings Inc

NYSE:DNA

DNA Rankings

DNA Stock Data

2.17B
1.12B
6.74%
83.82%
12.58%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Boston

About DNA

the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.